Abnova (Taiwan)TPE:4133 75 Return-on-Tangible-Equity is 3.55% as of Dec. 2025, which is 5% below its 10-year median of 3.74. GuruFocus rates TPE:4133 with a GF Score™ of 75/100 and a GF Value™ of NT$28.24 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,199 Biotechnology companies, Abnova (Taiwan) ranks better than 76.9% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Abnova (Taiwan)'s annualized net income for the quarter that ended in Dec. 2025 was NT$42.2 Mil. Abnova (Taiwan)'s average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$1,189.4 Mil. Therefore, Abnova (Taiwan)'s annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 3.55%.
The historical rank and industry rank for Abnova (Taiwan)'s Return-on-Tangible-Equity or its related term are showing as below:
TPE:4133'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -0.1 Med: 3.74 Max: 6.32
Current: -0.1
During the past 13 years, Abnova (Taiwan)'s highest Return-on-Tangible-Equity was 6.32%. The lowest was -0.10%. And the median was 3.74%.
TPE:4133's Return-on-Tangible-Equity is ranked better than 76.9% of 1199
companies
in the Biotechnology industry
Industry Median: -42.21
vs TPE:4133: -0.10
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Abnova (Taiwan) Return-on-Tangible-Equity Related Terms
Abnova (Taiwan) Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Abnova (Taiwan)'s Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4133 vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Abnova (Taiwan)'s Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abnova (Taiwan) Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abnova (Taiwan)'s Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Abnova (Taiwan)'s Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 3.55% mean?
Abnova (Taiwan) (TPE:4133) has a Return-on-Tangible-Equity of 3.55% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Abnova (Taiwan) and its competitors. This is near median its historical median of 3.74. According to the industry distribution chart, Abnova (Taiwan) ranks #277 out of 1199 companies in the Biotechnology industry, placing it in the top 23.1%.
Is Abnova (Taiwan)'s Return-on-Tangible-Equity too high?
Abnova (Taiwan)'s current Return-on-Tangible-Equity of 3.55% is near median its 10-year median of 3.74. Based on the distribution chart, Abnova (Taiwan) ranks #277 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Abnova (Taiwan) has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abnova (Taiwan)'s Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abnova (Taiwan) ranks #277 out of 1199 companies for Return-on-Tangible-Equity. This places Abnova (Taiwan) in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Abnova (Taiwan) and its competitors. Abnova (Taiwan)'s current Return-on-Tangible-Equity is 3.55%, which is near median its own 10-year median of 3.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abnova (Taiwan) stock overvalued right now?
Based on GuruFocus' analysis, Abnova (Taiwan) (TPE:4133) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$28.24, compared to a current price of NT$20.80 — trading 26.3% below its estimated fair value. The current Return-on-Tangible-Equity is 3.55%, which is near median its 10-year median of 3.74. Abnova (Taiwan)'s overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Abnova (Taiwan) (TPE:4133), the current Return-on-Tangible-Equity is 3.55% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abnova (Taiwan) (TPE:4133) Overvalued in 2026?
Based on GuruFocus' analysis, Abnova (Taiwan) stock appears to be undervalued.
The current stock price of NT$20.80 is trading 26.3% below its estimated GF Value™ of NT$28.24.
GuruFocus considers Abnova (Taiwan) to be Modestly Undervalued.
Key valuation signals for TPE:4133:
Return-on-Tangible-Equity: 3.55% (near median its 10-year median of 3.74)
GF Value™: NT$28.24 vs. price of NT$20.80 (26.3% below fair value)
No single metric tells the full story. See the TPE:4133 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abnova (Taiwan) Corp is engaged in developing, manufacturing, and selling monoclonal antibody, polyclonal antibody, proteins, medical inspection instruments and testing reagents, which are mainly antibody reagents, antibody chips or related products provided to and used by academic, research institutions or pharmaceutical factories. Geographically, it operates in America, Europe, Taiwan and Other Countries. It generates maximum revenue from America. Its products include: SARS-CoV/CoV-2, DNA, RNA new, Proteins/peptides, MaxPab, DNAxPab, Polyclonal Ab, Monoclonal Ab and Others. The company's services are: Gene synthesis & cytogenetics, Peptide services, Protein expression, Humanized antibody, Assay development, Conjugation, FFPE tumor tissue DNA, In situ hybridization (ISH) and Others.
75GF Score
Get the complete analysis for TPE:4133
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4133 has been successfully added to your 
